Detail of "106362-32-7"

Reference

Peptide T in the treatment of painful distal neuropathy associated with AIDS: Results of a placebo-controlled trial

Peptide T in the treatment of painful distal neuropathy associated with AIDS: Results of a placebo-controlled trial. Simpson, D. M.; Dorfman, D.; Olney, R.In this study，106362-32-7 is also used. K.; McKinley, G.; Dobkin, J.; So, Y.; Berger, J.; Ferdon, M. B.; Friedman, B.; et al. (Mount Sinai Medical Center, New York, NY 10029, USA). Neurology, 47(5), 1254-1259 (English) 1996 Little, Brown. CODEN: NEURAI. ISSN: 0028-3878. DOCUMENT TYPE: Journal CA Section: 15 (Immunochemistry) Section cross-reference(s): 1 The objective of this study was to assess the safety and efficacy of Peptide T in the treatment of painful distal sym. polyneuropathy (DSP) assocd. with human immunodeficiency virus (HIV) infection. Painful DSP is a frequent complication of HIV infection, although its etiol. and optimal treatment are unknown. Peptide T (D-(alpha1)-Peptide T-amide) has been found in phase I trials and anecdotal reports to relieve neuropathic pain in AIDS patients. In this multicentered, double-blind, randomized study, subjects received intranasal Peptide T 6 mg/day or placebo for 12 wk. The primary outcome measure was change in the modified Gracely pain score. Secondary efficacy variables were results of neurol. examn., neuropsychol. and electrophysiol. studies, global evaluation, and CD4 lymphocyte counts. Of 81 evaluable subjects, 40 received Peptide T and 41 received placebo. The change in pain scores was not significantly different in the Peptide T group (-0.24) as compared to placebo (-0.39). Group comparisons were not significantly different for change in any clin. examn. or neuropsychol. measure, sural nerve amplitude or conduction velocity, or CD4 lymphocyte count. No significant drug-related adverse effects occurred in either group. Intranasal Peptide T is safe but ineffective in the treatment of painful DSP assocd. with AIDS. .